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H I G H L I G H T S
• Subjects with clinical FH had elevated risks of stroke/TIA and PVD in addition to theraised risk of coronary heart disease.• Undiagnosed FH subjects had much greater risks of all CVD outcomes than subjects with clinical FH diagnosis.• Only 75% of the FH subjects were on lipid-lowering treatment, and only 38% of those on treatment were on high-potency statins.
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A B S T R A C T
Background and aims: Familial hypercholesterolaemia (FH) is a known major cause of premature heart disease.
However, the risks of atherosclerotic disease in other vascular regions are less known. We determined the risk of
major cardiovascular disease (CVD) outcomes associated with clinical FH.
Methods: In a retrospective cohort study (1 January, 1999 to 22 July, 2016), we randomly-matched 14,097 UK
subjects with clinical FH diagnoses or characteristics (Simon-Broome definite or Dutch Lipid Clinic Score> 8) to
42,506 subjects without FH by age, sex, general practice. We excluded those with CVD at baseline. Incident rates
for coronary heart disease (CHD), stroke or transient ischaemic attack (TIA) and peripheral vascular disease
(PVD) were estimated. Cox proportional hazards regression, stratified on matched-pairs, determined adjusted
hazards ratios (HR) for incident CVD.
Results: During follow-up (median 13.8 years), incidence rates (95% CI) of CVD (per 1000 person-years) were
25.6 (24.8–26.3) in FH and 2.9 (2.8–3.1) in non-FH subjects. The risk of CHD, stroke/TIA and PVD was higher in
FH compared to non-FH subjects: CHD (HR 10.63, 95% CI 9.82–11.49), stroke/TIA (HR 6.74, 95% CI
5.84–7.77), PVD (HR 7.17, 95% CI 6.08–8.46). The risk of CVD was greater in those with FH characteristics (HR
13.52, 95% CI 12.48–14.65) than those with clinical diagnoses (HR 1.66, 95% CI 1.42–1.93).
Conclusions: In addition to the recognised increased risk of CHD, subjects with FH have greatly elevated risk of
stroke/TIA and PVD. This emphasises need for early diagnosis and preventive interventions beyond CHD, to
reduce CVD risk in these individuals.
1. Introduction
Familial hypercholesterolemia (FH) is a common monogenic auto-
somal dominant disorder causing raised low-density lipoprotein (LDL)
cholesterol from birth. It affects up to 250,000 individuals in the UK,
with an estimated prevalence of 1/270 individuals in the general
population with the heterozygous form [1–3]. Untreated FH is asso-
ciated with a substantially higher risk of coronary heart disease (CHD)
and premature death [4], but lipid-lowering therapy improves prog-
nosis [5,6], reducing risk of coronary heart disease and all-cause mor-
tality by at least 44% in patients with heterozygous FH treated with
moderate-to high-intensity statins [5–8].
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In England, the National Institute for Health and Care Excellence
(NICE) guidelines, updated in 2017 [8], recommend that individuals
with raised cholesterol levels in primary care are assessed for a clinical
diagnosis of FH using Simon-Broome, Dutch Lipid Clinic Network
(DLCN), or cholesterol above > 99th percentile. Following a clinical
FH diagnosis in primary care, these individuals should be referred for
lipid specialist diagnosis, management and screening relatives. The FH
diagnosis can be recorded in UK primary care electronic health records
(EHRs) using specific disease codes, following specialist referral and
diagnosis. Moreover, there are also undiagnosed patients in primary
care with clinical characteristics (raised cholesterol, personal or family
history of CHD, or clinical signs) who have the phenotype for FH.
While the association of FH with premature CHD is well known, the
risk of atherosclerotic disease in other vascular regions among subjects
with FH is less clear, and evidence from previous studies is conflicting
[9–12]. This study sought to determine the cardiovascular disease risk
profile of subjects with FH in the general population using longitudinal
data from patients’ primary care electronic health records. We assessed
the incidence and risks of CHD, stroke/transient ischaemic attacks and
peripheral vascular disease in subjects in primary care with clinical FH.
2. Materials and methods
2.1. Study design and data source
We conducted a retrospective matched cohort study using data from
the Clinical Practice Research Datalink (CPRD). The CPRD is a large
nationally representative electronic database of anonymised primary
care data of subjects in the UK. It includes data from over 20 million
patient lives with over 5 million patients currently registered and ac-
tive. The database contains information on patient characteristics,
symptoms, clinical diagnoses, laboratory test results, medication pre-
scriptions and referrals to secondary care [13]. Access to the data and
ethical approval was granted by the CPRD Independent Scientific Ad-
visory Committee (Protocol number 16_191R2).
2.2. Study population
We identified all adults with FH in primary care during the study
period: 1 January 1999 to 22 July 2016. This study cohort comprised
subjects who had at least one cholesterol measurement (total choles-
terol or low-density lipoprotein cholesterol) during the study period
with either:
− a documented FH diagnosis, or
− the clinical phenotype of definite FH using the Simon Broome (SB)
or Dutch Lipid Clinic Network (DLCN) criteria [1].
Subjects’ follow-up started only after they had contributed one year
of records in their general practice. Subjects who had disease (Read)
codes suggesting pre-existing CVD (coronary heart disease, stroke,
transient ischaemic attack or peripheral vascular disease) prior to the
start of their follow-up were excluded.
Each subject with FH was individually matched to three control
subjects without FH, by 5-year age-bands, sex and general practice to
eliminate confounding by these variables. Eligibility criteria for subjects
without FH were: cholesterol testing done within six months of the
follow-up start date of their matched FH case, no documented diagnosis
of FH and no pre-existing CVD.
All subjects were followed up until their first diagnosis of cardio-
vascular disease. Subjects who did not develop CVD were followed up
until date of death, transfer out of the practice or study end date,
whichever occurred first.
2.3. Covariates
All analyses were stratified on the matched pairs and therefore
controlled for any confounding effect of age, sex and general practice.
We collected data on other demographic variables such as ethnicity,
lifestyle, medication and comorbidities that could potentially confound
the relationship between FH and future CVD in this cohort. Included in
the analyses were, baseline records of smoking status, history of alcohol
misuse, obesity/overweight, hypertension, type 1 diabetes (T1DM),
type 2 diabetes (T2DM), rheumatoid arthritis and other inflammatory/
immunological conditions, chronic kidney disease, atrial fibrillation,
treatment with lipid-reducing medication, potency of prescribed statins,
use of antipsychotics, corticosteroid use and family history of pre-
mature CHD. We also adjusted for any effects of potential improvement
in FH management on the risk of CVD, due to the publication of NICE
guidelines, by indicating whether follow-up started before or on/after
2008 for subjects in the cohort.
2.4. Outcome ascertainment
Incident cardiovascular disease was defined as any new clinical
diagnosis of coronary heart disease, stroke/transient ischaemic attack
(TIA) or peripheral vascular disease. These were identified from sub-
jects’ primary care EHRs during the study period, as were mortality and
date of death. Disease codes used for cardiovascular disease are shown
in the supplementary online files.
2.5. Sample size calculation
Based on findings from previous research [14], we estimated a
minimum hazard ratio of 1.2 for overall atherosclerotic CVD risk. To
achieve this, a minimum total cohort size of 9450 individuals was re-
quired with an expectation of 1265 CVD events at 90% power and
significance level of 0.05 (two-sided test of significance). Matching one
FH subject to three controls allowed for optimum statistical power for
the analysis based on previous recommendations [15].
2.6. Statistical analyses
Baseline descriptive analyses were performed for all subjects in the
cohort and results were represented as number (%), mean (SD) and
median (IQR) for categorical, normal continuous and non-normal
continuous variables respectively. Missing variables were presented in
result tables. Appropriate statistical tests such as chi-squared, t-tests
and analyses of variance tests (ANOVA) were used to assess differences
between the groups of interest. The incidence rates of CVD were de-
termined for FH and non-FH groups, presented per 1000-person years at
risk. Cox proportional hazards regression was used to derive hazards
ratios for first onset of any CVD and secondarily, hazards ratios for the
various major CVD subtypes - CHD, stroke/TIA and peripheral vascular
disease, for subjects with FH compared to those without FH. Analyses
were stratified on the matched variables and also adjusted for in-
dividuals’ demographics, lifestyle factors, comorbidities and prescribed
medication use as listed above. Confounder selection used the change-
in-estimate criteria [16], and any covariate which changed the effect
size of the univariate exposure-outcome model by 10% was considered
an important confounder and included in the fully-adjusted model.
Statistical tests of the proportional hazards assumption found the Cox
proportional hazards regression to be suitable for the analyses. In
subjects with missing or unrecorded categorical clinical variables, the
common assumption was made that these individuals did not have the
condition. Multiple imputation, the standard epidemiological approach
used in research studies to provide unbiased estimates for missing va-
lues when data are assumed to be missing at random [17], was used to
estimate missing BMI data. Complete case analyses was adopted in the
analyses of other continuous variables with missing data, such as
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Triglycerides. All analyses were performed using STATA SE15.
2.7. Sensitivity analyses
Since lower levels of triglycerides are associated with higher rates of
detection of FH mutation in subjects with a clinical diagnosis of FH
[18,19], we evaluated the effect of limiting analyses to a subset of those
with stringent lipid criteria for FH. We also assessed the impact of FH
diagnosis on CVD risk by performing separate analyses on subjects with
recorded diagnoses of FH and those undiagnosed subjects with the
clinical phenotype (Simon-Broome definite or DLC Score>8).
3. Results
3.1. Cohort characteristics
There were 3,936,934 subjects in CPRD with records of either total
or LDL-cholesterol measurement between 1 January 1999 and 22 July
2016. Among these, 14,097 subjects had clinical FH and no prior his-
tory of cardiovascular disease at baseline. This comprised 5152 subjects
with documented diagnosis of FH in the EHR, and 8945 subjects who
had no documented FH diagnosis but had the clinical phenotype of FH
based on SB or DLCN diagnostic criteria for definite FH. Of these
identified subjects, 53.3% were females, the mean age at the start of
follow-up was 42 years, and mean body-mass index was 27.3 kg/m2. FH
subjects were matched with 42,506 non-FH subjects. As individuals
with and without FH were matched on age and sex, the distribution of
these characteristics was similar in both groups. The median follow-up
time for FH and non-FH subjects was 13.8 years (IQR 8.4–17.7 years)
and the average follow-up in person-years for subjects with and without
FH was 174,950 and 588,470 person-years, respectively.
The baseline demographic and clinical characteristics of subjects
with and without FH are shown in Table 1. As expected, there was a
significantly higher proportion of FH subjects with a family history of
premature coronary heart disease than non-FH subjects (5.1% vs. 2.7%,
p < 0.001); and more FH than non-FH subjects were on lipid-lowering
medication at the start of the study (19.1% vs. 4.7%, p < 0.001).
Ethnicity records were missing in 85% of subjects, but in those where it
was recorded, 80% were White Caucasian. BMI records were available
for 40% of subjects, so multiple imputation with chained equations was
used to estimate missing BMI values.
3.2. Lipid characteristics of the cohort
For subjects on statins or other cholesterol-lowering medications
with known potency, the corrected levels of baseline cholesterol were
estimated from observed levels, based on estimated percentage reduc-
tion in LDL-cholesterol with statins of different potencies [20]. As ex-
pected, the mean total cholesterol concentration was significantly
higher in those with FH (9.30 [SD 2.6] mmol/L) compared to those
without FH (5.98 [SD 1.6] mmol/L), respectively. In FH and non-FH
subjects, mean LDL-cholesterol at baseline was 5.72mmol/L [SD 2.1]
and 3.63mmol/L [SD 1.1], respectively. Fig. 1 shows the distribution of
baseline LDL-cholesterol among subjects with and without FH.
3.3. Prescribing of statins and other lipid lowering treatments
At the start of the study, 19.1% of subjects with FH and 4.7% of non-
FH subjects were on lipid-lowering treatments. Over the duration of
follow-up, the proportion of FH and non-FH subjects on lipid-lowering
treatments increased to 75% and 20%, respectively. There was a mar-
ginal increase in the proportion of non-FH subjects prescribed high
Table 1
Baseline demographic and clinical characteristics of subjects with clinical FH and non-FH subjects.
Risk factor variable Unit FH subjects n= 14,097 Non-FH subjects n= 42,506 p-value
Age at start of study mean (SD) 42.5 (11.7) 41.6 (12.5)
Sex
Male n (%) 6578 (46.7) 19,843 (46.7)
Female 7519 (53.3) 22,663 (53.3)
Follow-up (years) median (IQR) 12.4 (7.1–16.8) 14.2 (8.8–17.8)
Body mass index kg/mb (SD) 27.8 (5.4) 26.2 (5.6) < 0.001
Alcohol misusea n (%) 265 (1.9) 712 (1.7) 0.106
Ever-smoked recordb (yes/no) n (%) 11,518 (81.7) 34,395 (80.9) 0.038
Hypertension n (%) 783 (5.6) 2393 (5.6) 0.736
Atrial fibrillation n (%) 35 (0.3) 120 (0.3) 0.503
Chronic kidney disease n (%) 57 (0.4) 127 (0.3) 0.056
Type 1 diabetes n (%) 60 (0.4) 247 (0.6) 0.029
Type 2 diabetes n (%) 311 (2.2) 726 (1.7) <0.001
Overweight/obesity n (%) 525 (3.7) 1307 (3.1) <0.001
Rheumatoid arthritis & other inflammatory diseases n (%) 100 (0.7) 285 (0.7) 0.626
Family history of coronary heart disease n (%) 712 (5.1) 1156 (2.7) <0.001
HIV n (%) 6 (0.04) 16 (0.04) 0.797
Antipsychotic use n (%) 491 (3.5) 1165 (2.7) <0.001
Oral corticosteroids n (%) 313 (2.2) 920 (2.2) 0.693
Immunosuppressant drugs n (%) 315 (2.2) 926 (2.2) 0.694
Lipid-lowering treatmentc n (%) 2692 (19.1) 2007 (4.7) <0.001
Lipid profiled (mmol/L)
Total cholesterol mean (SD) 9.30 (2.6) 5.98 (1.6)
LDL cholesterol mean (SD) 5.72 (2.1) 3.63 (1.1)
Triglyceride median (IQR) 2.10 (1.3–3.5) 1.30 (0.9–1.9)
Statin potency
Low n (%) 57 (0.4) 49 (0.1)
Medium 466 (3.3) 384 (0.9)
High 447 (3.2) 145 (0.3)
Non-statin lipid lowering medication n (%) 1722 (12.2) 1429 (3.4)
a Numbers indicate proportion of subjects with record of alcohol misuse.
b Numbers indicate proportion of subjects with record of ever-smoking.
c Lipid-lowering treatment include statins, fibrates and combination therapy (statins and ezetimibe).
d Total cholesterol and LDL-C correction done for patients on cholesterol lowering medication with known potency (based on percentage reduction in LDL-C
estimated in a previous study) (1).
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intensity statins, from 0.3% at baseline to 4.6% during follow-up. This
contrasts with a greater increase in high intensity statins prescribed in
FH subjects from 3.2% at baseline to 37.5% during follow-up. Table 2
shows the proportion of FH and non-FH subjects treated with lipid-
lowering medication of different potencies, at baseline and during the
period of follow-up (also shown in Supplemental Fig. 2).
3.4. Cardiovascular disease outcomes
There were a total of 6202 incident cases of cardiovascular disease
(CHD, stroke, TIA or PVD) during follow-up. These were identified in
31.7% of individuals with FH and 4.1% of non-FH individuals. Clinical
risk factors for CVD such as hypertension, type 2 diabetes, higher body
mass index and male sex were more prevalent in FH subjects who were
diagnosed with CVD than those who remained free of CVD during
follow-up. The prevalence of CKD, atrial fibrillation and baseline LDL-
cholesterol levels did not differ significantly between the FH subjects
who developed CVD and those who did not. Unexpectedly, smoking
prevalence was significantly higher in FH subjects who did not develop
CVD compared to those who did (Supplemental Table A).
Overall, the incidence rates of CVD among FH and non-FH in-
dividuals (per 1000 person-years at risk) were 25.6 and 2.9, respec-
tively. The incidence rate in FH compared to non-FH individuals was
highest for CHD (incidence rate 20.3 versus 2.0), with incidence rates of
stroke/TIA and PVD also higher among those with FH compared to non-
FH individuals (Table 3). The overall mean age at first diagnosis of
CHD, stroke/TIA and PVD was 53.3 years, 56 years and 55.5 years,
respectively. CVD outcomes were diagnosed approximately 10 years
earlier in those with FH compared to those without FH.
3.5. Hazards ratio of cardiovascular disease
Table 4 shows the number of CVD events and hazards ratios for all
CVD subtypes among FH and non-FH subjects. FH subjects were more
likely to have incident CVD than non-FH subjects (hazards ratio [HR]
9.14, 95% CI 8.55–9.76, p < 0.001). This comprised higher risk of
incident CHD (HR 10.63, 95% CI 9.82–11.49, p < 0.001), stroke/TIA
(HR 6.74, 95% CI 5.84–7.77, p < 0.001) and peripheral vascular dis-
ease (HR 7.17, 95% CI 6.08–8.46, p < 0.001). Adjustment for demo-
graphic factors, clinical covariates, LDL-cholesterol levels and the effect
of the 2008 NICE guidelines resulted in no major change in these ha-
zard ratios (< 10% change-in-estimate criteria).
Stratifying the analysis between FH and various CVD outcomes by
sex, demonstrated a statistically significant higher risk of all the dif-
ferent CVD endpoints within sexes (p < 0.001 for all endpoints in
males and females). Compared to subjects of the same sex, the higher
CHD risk among males with FH was markedly higher than the higher
risk among females with FH (Fig. 2). Between-sex comparisons showed
statistically higher hazards ratio for all CVD outcomes associated with
FH, in males compared with females (p < 0.001 for all CVD end-
points).
3.6. Sensitivity analyses
On restricting analyses to a subset of FH subjects with total cho-
lesterol> 7.5mm/l and triglycerides< 3.5mmol/L, the hazards ratios
for all CVD outcomes including stroke/TIA and peripheral vascular
disease remained substantially higher in subjects with FH compared to
those without FH (Table 5). The hazards ratio estimates for these out-
comes were, however, lower than estimates from the primary analyses.
Fig. 1. Distribution of LDL-cholesterol levels (millimoles/litre) in FH and non-FH subjects.
Each bar's height represents the percentage of subjects in that category. Height of the bars are scaled so that the sum of heights equals 100.
Table 2
Proportion of subjects of lipid-lowering therapy of different potencies.
Study period
Low potency statin (%) Medium potency statin (%) High potency statin (%) Other LLT (%) No LLT (%)
FH Non FH FH Non FH FH Non FH FH Non FH FH Non FH
Start of study 0.40 0.10 3.30 0.90 3.20 0.30 12.20 3.40 80.9 94.3
Study follow-up 1.98 1.22 35.61 14.06 37.54 4.60 0.41 0.27 24.46 79.86
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Further restriction to a smaller subgroup of FH subjects with trigly-
cerides 2.16 or less, resulted in even lower hazards ratio estimates for
CVD than the subgroup with triglycerides< 3.5mmol/L. There also
remained higher risk of all CVD outcomes in this subgroup of FH sub-
jects compared to non-FH subjects (Supplemental Table B).
Separate analyses of CVD outcomes in diagnosed FH subjects and
those with FH characteristics who were undiagnosed, showed a higher
risk of CHD in both groups of patients. Compared to subjects without
FH, subjects with undiagnosed FH had markedly elevated hazards ratio
for CHD (HR 15.32, 95% CI 13.91–16.88, p < 0.0001) as well as sig-
nificantly elevated risk of other CVD subtypes such as stroke/TIA and
PVD (Table 6). In patients with documented FH diagnoses, there was
also a significant but marginally higher risk of CHD compared to non-
FH subjects (HR 2.05, 95% CI 1.72–2.45, p < 0.0001). There was no
statistically significant difference in the risk of stroke/TIA and PVD
among diagnosed FH subjects compared to non-FH subjects. At the start
of the study, lipid lowering treatments were prescribed in 12.2% of
undiagnosed subjects with FH phenotype and 31.0% of diagnosed FH
subjects. During follow-up, the proportion on treatment increased to
74.4% and 77.6%, respectively.
4. Discussion
4.1. Summary of principal findings
This large cohort study has found subjects with clinical FH have
significantly increased risks of all major types of CVD, which occurred
at a younger age, compared with age- and sex-matched subjects without
FH. Diagnosed FH subjects had a two-fold higher risk of CHD than
subjects without FH. Subjects with undiagnosed FH had a 15-fold
higher risk of CHD as well as higher risks of stroke/TIA and PVD. Using
stringent lipid thresholds (elevated cholesterol/low triglycerides) to
determine FH phenotypes still maintained elevated risk of CVD in FH
subjects.
4.2. Comparison with existing literature
Few studies have assessed the risk of CVD outcomes in primary care
subjects with a clinical diagnosis of FH. Similar to our study, elevated
risks of CHD and total atherosclerotic CVD were demonstrated in a
Spanish multi-centre prospective cohort study of molecularly defined
Table 3
Incidence rate of CVD outcomes in FH and non-FH subjects.
CVD outcome
Age in years at first CVD event (mean (SD)) Number of new events Rate per 1000 person-years (95% CI) p-value for CVD rate ratio
FH subjects Non-FH subjects FH subjects Non-FH subjects FH subjects Non-FH subjects
Any cardiovascular disease 4474 1728 25.6 (24.8–26.3) 2.9 (2.8–3.1) < 0.0001
Coronary heart disease 50.7 (7.5) 61.1 (10.9) 3545 1173 20.3 (19.6–20.9) 2.0 (1.9–2.1) < 0.0001
Stroke/TIA 51.9 (8.5) 63.7 (11.2) 764 405 4.3 (4.1–4.7) 0.7 (0.6–0.8) < 0.0001
Peripheral vascular disease 52.4 (8.2) 61.7 (10.9) 592 295 3.4 (3.1–3.7) 0.5 (0.4–0.6) < 0.0001
Person-time at risk for subjects with FH (1000 person-years): 174.95.
Person-time at risk for non-FH subjects (1000 person-years): 588.47.
Table 4
Hazards ratios for CVD outcomes among subjects identified with FH.
CVD outcome
Total n (%)
N=56,603
FH n (%) n=14,097 Non-FH n (%) n=42,506 HRa for CVD (95% CI)
All CVD outcomes 6202 (11.0) 4474 (31.7) 1728 (4.1) 9.14 (8.55–9.76)
Coronary heart disease 4718 (8.3) 3545 (25.2) 1173 (2.8) 10.63 (9.82–11.49)
Stroke/TIA 1169 (2.1) 764 (5.4) 405 (1.0) 6.74 (5.84–7.77)
Peripheral vascular dx 887 (1.6) 592 (4.2) 295 (0.7) 7.17 (6.08–8.46)
a Hazards ratios derived using Cox regression models stratified on matched pairs, with matching done on age, sex and general practice.
Fig. 2. Hazards ratio for CVD outcomes in subjects with FH,
stratified by sex.
Each bar represents the hazard ratio for the CVD subtype
among FH and non-FH subjects of the same sex. The error
bars represent the 95% confidence intervals. All differences
between males and females were statistically significant
with p < 0.001 for all endpoints.
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FH patients [21] as well as a population-based study of patients with
clinical FH in the United States [14]. These studies did not, however,
evaluate the risk of PVD or TIA and stroke as separate entities. A more
recent cohort study of FH registry patients in Norway also found an
increased risk of CHD in subjects with genetically diagnosed FH, com-
pared to the general population [22]. Similar to other registry-based
researches [5,6], the excess CHD risk was highest in the youngest age
group with an increase in the relative risk of fatal and non-fatal CHD
before the age of 40 years, which decreases with increasing age
[5,6,22].
Previous research has shown that the risk of a fatal coronary event
associated with FH is greatest in the 20–39 year age group [23]. The
mean age of subjects in our study was 42 years, and may partly be due
to the fact that previously asymptomatic individuals become identified
in primary care during the UK NHS health check, which is offered to
adults aged between 40 and 74 years [24]. In addition, in patients less
than 40 years, a clinical diagnosis of FH in primary care may only be
recognised after the first diagnosis of CVD. We adjusted for the effect of
age in the univariate association of FH with CVD but found no sig-
nificant attenuation of the hazard ratio (not shown). As age did not
change the hazard ratio by up to 10%, it was not considered a sig-
nificant confounder of the association of FH with CVD in our study.
We found that only 36% of the subjects with clinical FH had a
documented diagnosis, and only 19% of all FH subjects were on lipid-
lowering treatment at baseline (comprising 12.2% of undiagnosed FH
subjects and 31% of subjects with documented FH diagnosis). This is
consistent with findings of underdiagnoses and suboptimal treatment of
phenotypic FH patients in a European Mediterranean primary care
population [25]. The much higher risk of CHD among undiagnosed FH
subjects who were not optimally treated also corroborates findings from
a Danish population-based study [26], which demonstrated a much
higher FH-associated risk of CHD in FH subjects not on cholesterol-
reducing medication compared to those on treatment with cholesterol-
reducing medication.
Several studies assessing the risk of stroke in subjects with FH
provide conflicting results [9,10,12]. A recent study found no associa-
tion between genetically-confirmed FH and ischaemic stroke risk;
however, clinical FH, according to DLCN criteria, was found to be as-
sociated with a 2.5-fold higher risk of ischaemic stroke which may,
perhaps, be attributed to the DLCN diagnostic criteria of personal pre-
mature CHD [10].
In patients with treated FH in the Simon Broome register, the risk of
fatal stroke was not significantly increased when compared with the
general population [9]. This may be due to regular monitoring of
subjects in the register, resulting in the early identification and man-
agement of hypertension, and the consequent reduction of risk of stroke
[10]. It was suggested by the Simon Broome study authors that the
finding may be due to possible underestimation of stroke risk, with
susceptible individuals dying from CHD at much earlier ages. With the
current trend to reduction in MI and CHD mortality, there may be an
increase in the incidence of other CVD events, like stroke and PVD.
A few small-scale studies in the pre-statin era demonstrated an as-
sociation between FH and stroke. An increased risk of familial hy-
perlipidaemia was found in a small study of young patients with non-
embolic ischaemic stroke of unknown aetiology [27]. Another study
reported higher prevalence of carotid bifurcation atherosclerosis in
patients with FH [28]. Ischaemic stroke risk was also shown to be 20
times higher in subjects with heterozygous FH than in the general
Finnish population [12].
We found that FH subjects who developed CVD had a higher BMI as
well as higher prevalence of hypertension and type 2 diabetes than FH
subjects who did not develop CVD. This is consistent with findings from
the Spanish SAFEHEART cohort study of patients with FH, which
showed that male sex, high blood pressure and increased BMI were
Table 5
Hazards ratios for CVD outcomes among the subgroup of FH subjects with total cholesterolb> 7.5 and triglycerides< 3.5.
CVD outcome
Total n (%)
N=23,027
FH n (%) n=6318 Non-FH n (%) n=16,709 HRa for CVD (95% CI)
All CVD outcomes 2501 (10.9) 1703 (27.0) 798 (4.8) 6.19 (5.62–6.83)
Coronary heart disease 1884 (8.2) 1352 (21.4) 532 (3.2) 7.29 (6.49–8.19)
Stroke/TIA 503 (2.2) 298 (4.7) 205 (1.2) 4.42 (3.60–5.45)
Peripheral vascular dx 346 (1.5) 218 (3.5) 128 (0.8) 5.02 (3.91–6.45)
a Hazards ratios derived using Cox regression models stratified on matched pairs.
b Total cholesterol correction done for subjects on cholesterol lowering medication with known potency (based on estimated percentage reduction in LDL-C with
statin potency [19].
Table 6
Hazards ratios for CVD in GP-diagnosed FH and undiagnosed (phenotypic) FH subjects.
CVD outcome
Total n (%) FH patients Non-FH subjects Unadjusted hazards ratio for CVD (95% CI) p-value
Subjects with FH diagnosis
N=20,796 n=5152 n=15,644
All CVD outcomes 883 (4.3) 301 (5.8) 582 (3.7) 1.66 (1.42–1.93) < 0.0001
Coronary heart disease 613 (3.0) 240 (4.7) 373 (2.4) 2.05 (1.72–2.45) < 0.0001
Stroke/TIA 186 (0.9) 37 (0.7) 149 (1.0) 0.77 (0.52–1.14) 0.188
Peripheral vascular dx 141 (0.7) 41 (0.8) 100 (0.6) 1.47 (0.99–2.19) 0.056
Subjects with phenotype for FH but no diagnosis
N=35,807 n=8945 n=26,862
All CVD outcomes 5319 (14.9) 4173 (46.7) 1146 (4.4) 13.52 (12.48–14.65) < 0.0001
Coronary heart disease 3933 (11.0) 3167 (35.4) 766 (2.9) 15.32 (13.91–16.88) < 0.0001
Stroke/TIA 830 (2.3) 616 (6.9) 214 (0.8) 10.92 (9.02–13.22) < 0.0001
Peripheral vascular dx 556 (1.6) 390 (4.4) 166 (0.6) 8.47 (6.80–10.54) < 0.0001
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independent predictors of atherosclerotic CVD in FH [21]. Similar
findings of significant and independent association between clinical risk
factors and CVD risk in individuals with FH was also demonstrated in a
systematic review [29]. Interestingly, unlike the SAFEHEART study, our
study findings did not demonstrate a positive association between
smoking and CVD in subjects with FH and we found no significant
difference in baseline LDL-cholesterol levels in FH subjects who de-
veloped CVD compared to those who did not.
4.3. Strengths and limitations
To our knowledge, this is the first study to identify elevated risk of
the diverse range of CVD outcomes in patients with clinical diagnoses of
FH in a real-world clinical setting. The use of an established and quality
assured database of comprehensively coded clinical data from subjects’
primary care records [13] has allowed us to robustly investigate the
associations between FH and CVD outcomes using a large sample size
and prospective longitudinal design, minimising selection or recall bias.
We identified subjects with clinical FH using specific disease coding
for FH as well as clinical phenotype based on standard diagnostic cri-
teria (Simon Broome and Dutch Lipid Clinic Network). This study co-
hort represents clinical FH subjects found in the general clinical po-
pulation setting and so, the CVD risk estimates from this large study can
be confidently generalised to subjects identified with clinical FH in ‘real
world’ primary care practice. Further, the highly elevated risk of CHD
found in the study is entirely consistent with that found in specialist
settings and disease registers, thereby underlining the validity of the
clinical FH cohort identified here, and the applicability of new findings
for risk of stroke and PVD.
The FH mutation-detection rate among patients with clinical FH is
high at total cholesterol levels greater than 9.3 mmol/l or with low
triglyceride levels [30], and those with raised triglycerides are less
likely to have genetically confirmed FH. To further increase robustness
of our findings, we performed sensitivity analyses with a subgroup of
subjects with lower triglyceride levels and this demonstrated consistent
findings for the association between CHD, stroke/TIA and PVD risk with
FH.
While study size and design have enabled the risk of CVD outcomes
in the identified population to be determined with considerable preci-
sion, we recognise some limitations. As with all clinical database ana-
lyses, findings are dependent on the quality of information entered.
Although this is quality assured in practices contributing to CPRD [13],
there will be incomplete recording of some lifestyle CVD risk factors, as
well as some coded diagnoses and comorbidities. For instance, the
nature of disease coding in the electronic health records did not specify
if diagnosed FH subjects in this cohort were genetically confirmed.
Genetic testing for FH is not yet widely available across the UK, so it is
likely that diagnosis of FH by specialists were based on clinical criteria.
We also acknowledge that inadequate primary care assessment or
documentation of premature CHD family history and other clinical
features of FH such as premature corneal arcus and tendinous xantho-
mata [31,32] may have led to FH under-identification or mis-
classification. For instance, the prevalence of type 2 diabetes was
slightly higher among FH subjects (2.2%) than non-FH subjects (1.7%).
This may indicate that subjects with co-existing type 2 diabetes and
CVD have been excluded, or may indicate potential misclassification of
hypercholesterolaemia as FH rather than due to secondary causes such
as diabetes. However, the prevalence is actually lower than prevalence
of type 2 diabetes in genetically-confirmed FH subjects (5.9%) in a
recent EU registry study [33]. The selection criteria for non-FH subjects
included cholesterol testing within six months of their matched FH
cases, so these individuals represent a cohort of high-risk subjects who
are being monitored with regular cholesterol testing. Furthermore,
because of the overlap in distribution of lipid level in FH and non-FH
subjects, a proportion of non-FH subjects may have cholesterol con-
centrations which are high enough to be compatible with an FH
diagnosis, for example having a “polygenic” and not a monogenic cause
[34]. As a consequence of these factors, this study may have in fact
underestimated the CVD risk of FH compared to the general population.
Finally, data on adherence to lipid-lowering treatments is not
available in routine electronic health records. Data on cholesterol levels
during follow-up were also not collected in this study, so we were un-
able to ascertain the proportion of FH subjects on statins who were
being treated to target. A recent UK study has shown variation in LDL-
cholesterol lowering in the general population of patients on statins,
demonstrating that those patients not achieving LDL targets have in-
creased risk of CVD [35]. We found that a higher proportion of diag-
nosed FH subjects were on lipid-lowering treatments compared with
undiagnosed FH subjects, and the risk of CVD outcomes were much
higher in undiagnosed subjects than those with documented diagnosis.
We therefore speculate that the inflated CVD risk in undiagnosed FH
subjects is due to sub-optimal management of these subjects. We also
cannot rule out the probability that subjects with a known FH diagnosis
are more likely to engage with intensive lifestyle modification and other
CVD-risk lowering interventions than subjects without a known diag-
nosis.
4.4. Clinical implications
The findings of higher risk of stroke/TIA and PVD in addition to
CHD risk, particularly in phenotypic undiagnosed FH subjects, under-
score the vital importance of better and earlier identification of subjects
with clinical FH. Primary care may be particularly well placed to do this
in the general population. However, the finding that over the duration
of the study, only 75% of the clinical FH patients in our cohort were on
any lipid-lowering treatment, and only 38% of those on lipid-lowering
treatment were on high-potency statins, is of serious concern and needs
to be addressed. While this demonstrates that primary care practi-
tioners are recognising and commencing treatment for patients with
high cholesterol, it also highlights the fact that a majority of these FH
subjects are probably not being referred to lipid clinics. These patients
are not likely optimally managed with the level of statin treatment
recommended by the NICE guidelines [8].
Knowledge of this increased cardiovascular disease burden, at a
young age, should inform appropriate strategies for policy, practice and
patient awareness. The current emphasis in prevention and manage-
ment of FH in both primary and specialist care is to reduce increased
risk of CHD [8,36]. Such care pathways should also focus on intensive
lifestyle modification and treatment to reduce the risk of stroke/TIA
and PVD.
4.5. Conclusions
Individuals with FH have been shown to have greatly increased risk
of a range of CVD outcomes, including not only CHD but also stroke,
TIA and PVD. This has important clinical implications and emphasises
the need for improved case identification of clinically recognisable FH
in the general population for targeted preventive intervention.
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